Last reviewed · How we verify
fluticasone propionate hydrofluoroalkane (HFA)
Fluticasone propionate HFA is a potent inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors.
Fluticasone propionate HFA is an inhaled corticosteroid developed by Organon and Co for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It works by reducing inflammation in the airways, thereby preventing symptoms such as wheezing and shortness of breath. Despite its effectiveness, it does not have an FDA label, which may limit its use in certain clinical settings. The drug has a well-established safety profile but includes common side effects like throat irritation and oral candidiasis. It competes in a crowded market of inhaled corticosteroids and combination therapies.
At a glance
| Generic name | fluticasone propionate hydrofluoroalkane (HFA) |
|---|---|
| Also known as | Flovent HFA |
| Sponsor | Organon and Co |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptors |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
It exerts its anti-inflammatory effects by inhibiting the production of inflammatory cytokines and chemokines, reducing the recruitment and activation of immune cells in the airways.
Approved indications
Common side effects
- Throat irritation
- Oral candidiasis
- Hoarseness
- Headache
Key clinical trials
- Advair HFA in Healthy and HAPE Predisposed Subjects (PHASE1, PHASE2)
- Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS). (PHASE2)
- Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418) (PHASE4)
- Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma (PHASE3)
- Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma (PHASE3)
- Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma (PHASE3)
- Fluticasone and Salmeterol in Allergic Rhinitis (PHASE4)
- A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
| US6228898B1 |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: